NPPA directs Pulse Oximeter & Oxygen Concentrators to submit MRP

The National Pharmaceutical Pricing Authority (NPPA) has directed all manufacturers / importers of Pulse Oximeter and Oxygen Concentrators to submit maximum retail price (MRP) details as per Para 29 of the Drugs Prices Control Order (DPCO) 2013 in the prescribed format within seven days i.e. latest by May 22, 2021 to regulate prices of these medical devices in the wake of C-19 pandemic.

This notice is in reference to the Gazette Notification dated March 31, 2020 issued by NPPA for regulation of medical devices under DPCO-2013 read with Essential Commodities (EC) Act, 1955 with effect from April 1, 2020.

 

Accordingly, MRP of medical devices cannot be increased more than ten per cent (10%) in a year.

In view of the above, all manufacturers or importers of aforesaid medical devices are hereby advised to ensure compliance of the provisions of Para 20 of the DPCO, 2013 failing which action may be initiated for violation of provisions of DPCO, 2013 read with EC Act, 1955.

“Medical devices industry associations of Pulse Oximeter and Oxygen Concentrator namely MTaI, AiMeD, CII, FICCI, USIBC, AMCHAM, AdvaMed are hereby directed to disseminate this office memorandum among its member companies and shall ensure compliance of the same,” NPPA in a notice stated.

 

NPPA had last year also directed manufacturers and importers of medical N-95 masks to submit MRP of medical N-95 masks. Manufacturers of N95 masks were also advised to obtain requisite certification from Bureau of Indian Standards (BIS) expeditiously.

Major manufacturers and importers of medical N95 masks have reduced their prices up to 67% of the MRP (the details of such manufacturers/importers has also been shared by the NPPA).

The national drug price regulator also shared the revised MRPs reported by these manufacturers of N-95 masks with the state drug controllers (SDCs).

The list indicates that the makers of N-95 masks reduced the cost of their products, some even up to 47 per cent, after NPPA issued an advisory on May 21, 2020 recommending manufacturers to voluntarily lower prices.

NPPA had also asked manufacturers, importers, suppliers of the N-95 masks to maintain parity in prices for non-government procurement and make them available at the same reasonable prices.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit